{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:15:28Z","timestamp":1792656928492,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.vaccine.2010.04.048","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T08:57:25Z","timestamp":1272617845000},"page":"4394-4401","source":"Crossref","is-referenced-by-count":67,"title":["Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector"],"prefix":"10.1016","volume":"28","author":[{"given":"J.","family":"Kortekaas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.M.","family":"Vloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.G.","family":"Antonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.M.","family":"Moormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2010.04.048_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3201\/eid0402.980218","article-title":"New vectors of Rift Valley fever in West Africa","volume":"4","author":"Fontenille","year":"1998","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2010.04.048_bib2","first-page":"35","article-title":"Rift Valley fever; transmission of the virus by mosquitoes","volume":"30","author":"Smithburn","year":"1949","journal-title":"Br J Exp Pathol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.04.048_bib3","first-page":"205","article-title":"The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs","volume":"44","author":"Coetzer","year":"1977","journal-title":"Onderstepoort J Vet Res"},{"issue":"1","key":"10.1016\/j.vaccine.2010.04.048_bib4","first-page":"11","article-title":"The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses","volume":"49","author":"Coetzer","year":"1982","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2010.04.048_bib5","first-page":"65","article-title":"Rift Valley fever","volume":"10","author":"Easterday","year":"1965","journal-title":"Adv Vet Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2010.04.048_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/345671","article-title":"Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans","volume":"36","author":"Al-Hazmi","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2010.04.048_bib7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2010.04.048_bib8","unstructured":"WHO. Outbreaks of Rift Valley fever in Kenya, Somalia and United Republic of Tanzania. December 2006\u2013April 2007. Wkly Epidemiol Rec 2007; 82(20):169\u201378."},{"issue":"48","key":"10.1016\/j.vaccine.2010.04.048_bib9","first-page":"417","article-title":"Outbreak news. Rift Valley fever, Sudan-update","volume":"82","author":"WHO","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"issue":"8","key":"10.1016\/j.vaccine.2010.04.048_bib10","first-page":"157","article-title":"Outbreak news. Rift Valley fever, Madagascar","volume":"83","author":"WHO","year":"2008","journal-title":"Wkly Epidemiol Rec"},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.048_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2010.04.048_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1743-422X-6-94","article-title":"Pathological studies on postvaccinal reactions of Rift Valley fever in goats","volume":"6","author":"Kamal","year":"2009","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.vaccine.2010.04.048_bib13","first-page":"155","article-title":"Rift Valley fever vaccine\u2014antibody and immune response in cattle to a live and an inactivated vaccine","volume":"50","author":"Barnard","year":"1979","journal-title":"J S Afr Vet Assoc"},{"issue":"1","key":"10.1016\/j.vaccine.2010.04.048_bib14","first-page":"45","article-title":"An inactivated rift valley fever vaccine","volume":"48","author":"Barnard","year":"1977","journal-title":"J S Afr Vet Assoc"},{"issue":"10","key":"10.1016\/j.vaccine.2010.04.048_bib15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2460\/ajvr.1980.41.10.1559","article-title":"Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep","volume":"41","author":"Harrington","year":"1980","journal-title":"Am J Vet Res"},{"issue":"2","key":"10.1016\/j.vaccine.2010.04.048_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2009.08.002","article-title":"Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines","volume":"84","author":"Bouloy","year":"2009","journal-title":"Antiviral Res"},{"issue":"11","key":"10.1016\/j.vaccine.2010.04.048_bib17","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/CVI.00182-09","article-title":"A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity","volume":"16","author":"Holman","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.048_bib18","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2010.04.048_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Rift Valley fever virus","volume":"234","author":"Bird","year":"2009","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"10.1016\/j.vaccine.2010.04.048_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","article-title":"Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins","volume":"366","author":"Gorchakov","year":"2007","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2010.04.048_bib21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2010.04.048_bib22","article-title":"A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge","author":"Mandell","year":"2009","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2010.04.048_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus","volume":"385","author":"N\u00e4slund","year":"2009","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2010.04.048_bib24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.vaccine.2010.01.001","article-title":"Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2010.04.048_bib25","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","article-title":"Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge","volume":"28","author":"de Boer","year":"2010","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2010.04.048_bib26","doi-asserted-by":"crossref","first-page":"10054","DOI":"10.1128\/JVI.78.18.10054-10063.2004","article-title":"A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV","volume":"78","author":"Huang","year":"2004","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2010.04.048_bib27","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1073\/pnas.0602566103","article-title":"Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease","volume":"103","author":"Park","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2010.04.048_bib28","first-page":"160","article-title":"Recombinant viruses of poultry as vector vaccines against fowl plague","volume":"119","author":"Fuchs","year":"2006","journal-title":"Berl Munch Tierarztl Wochenschr"},{"issue":"1","key":"10.1016\/j.vaccine.2010.04.048_bib29","first-page":"46","article-title":"Newcastle disease virus as a vaccine vector for humans","volume":"10","author":"Bukreyev","year":"2008","journal-title":"Curr Opin Mol Ther"},{"issue":"21","key":"10.1016\/j.vaccine.2010.04.048_bib30","doi-asserted-by":"crossref","first-page":"13275","DOI":"10.1128\/JVI.79.21.13275-13284.2005","article-title":"Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates","volume":"79","author":"Bukreyev","year":"2005","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2010.04.048_bib31","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1073\/pnas.0703584104","article-title":"Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens","volume":"104","author":"DiNapoli","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2010.04.048_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing antiviral B cell responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.048_bib33","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2010.04.048_bib34","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1128\/JVI.67.8.4822-4830.1993","article-title":"The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA","volume":"67","author":"Calain","year":"1993","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.04.048_bib35","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s007050070059","article-title":"Genome replication of Newcastle disease virus: involvement of the rule-of-six","volume":"145","author":"Peeters","year":"2000","journal-title":"Arch Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2010.04.048_bib36","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1128\/JCM.40.7.2323-2330.2002","article-title":"Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus. Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR","volume":"40","author":"Drosten","year":"2002","journal-title":"J Clin Microbiol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2010.04.048_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vetmic.2007.07.031","article-title":"Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo","volume":"127","author":"Paweska","year":"2008","journal-title":"Vet Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.04.048_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/viro.2000.0618","article-title":"Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation","volume":"278","author":"Krishnamurthy","year":"2000","journal-title":"Virology"},{"issue":"23","key":"10.1016\/j.vaccine.2010.04.048_bib39","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1128\/JVI.75.23.11868-11873.2001","article-title":"Recombinant Newcastle disease virus as a vaccine vector","volume":"75","author":"Nakaya","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.04.048_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins","volume":"357","author":"Gerrard","year":"2007","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2010.04.048_bib41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2010.04.048_bib42","series-title":"The molecular biology of the Paramyxovirus genus","author":"Galinski","year":"1991"},{"key":"10.1016\/j.vaccine.2010.04.048_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-4-1","article-title":"Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein","volume":"4","author":"Patch","year":"2007","journal-title":"Virol J"},{"issue":"1\u20134","key":"10.1016\/j.vaccine.2010.04.048_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01316748","article-title":"Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies","volume":"121","author":"Besselaar","year":"1991","journal-title":"Arch Virol"},{"issue":"1\u20134","key":"10.1016\/j.vaccine.2010.04.048_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01309641","article-title":"The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins","volume":"125","author":"Besselaar","year":"1992","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2010.04.048_bib46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-5-82","article-title":"Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins","volume":"5","author":"Liu","year":"2008","journal-title":"Virol J"},{"issue":"21","key":"10.1016\/j.vaccine.2010.04.048_bib47","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1128\/JVI.00919-06","article-title":"Nonsegmented negative-strand viruses as vaccine vectors","volume":"80","author":"Bukreyev","year":"2006","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2010.04.048_bib48","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.vaccine.2009.01.009","article-title":"Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans","volume":"27","author":"Dinapoli","year":"2009","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2010.04.048_bib49","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1128\/JVI.00713-07","article-title":"Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus","volume":"81","author":"DiNapoli","year":"2007","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.048_bib50","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00705-008-0099-5","article-title":"Experimental infection of calves with Newcastle disease virus induces systemic and mucosal antibody responses","volume":"153","author":"Subbiah","year":"2008","journal-title":"Arch Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2010.04.048_bib51","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host range restriction","volume":"77","author":"Park","year":"2003","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.04.048_bib52","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1128\/JVI.77.2.1501-1511.2003","article-title":"Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins","volume":"77","author":"Park","year":"2003","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.04.048_bib53","first-page":"418","article-title":"Interferon induction by Newcastle disease virus in mice","volume":"18","author":"Blach-Olszewska","year":"1970","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"10.1016\/j.vaccine.2010.04.048_bib54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/jir.1986.6.21","article-title":"Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic\u2013polycytidylic acid","volume":"6","author":"Brehm","year":"1986","journal-title":"J Interferon Res"},{"issue":"6","key":"10.1016\/j.vaccine.2010.04.048_bib55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","article-title":"Interferons alpha and beta as immune regulators\u2014a new look","volume":"14","author":"Biron","year":"2001","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.vaccine.2010.04.048_bib56","doi-asserted-by":"crossref","first-page":"10872","DOI":"10.1073\/pnas.1934678100","article-title":"Selective contribution of IFN-alpha\/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection","volume":"100","author":"Honda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2010.04.048_bib57","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni978","article-title":"Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon","volume":"4","author":"Le Bon","year":"2003","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2010.04.048_bib58","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1084\/jem.191.10.1777","article-title":"Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu\u2013PBL\u2013SCID mice","volume":"191","author":"Santini","year":"2000","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2010.04.048_bib59","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/JVI.80.3.1130-1139.2006","article-title":"Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector","volume":"80","author":"Martinez-Sobrido","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.04.048_bib60","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Betrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Arch Exp Path Pharmak"},{"key":"10.1016\/j.vaccine.2010.04.048_bib61","first-page":"227","article-title":"The method of right and wrong cases (constant stimuli) without Gauss's formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br J Psychol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10005542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10005542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:21:56Z","timestamp":1740054116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10005542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":61,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0264410X10005542"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.04.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}